Cabot Undervalued Stocks Advisor Weekly Update
There are three changes to the portfolio today.
Read More
pharmaceutical stock
Read More
pharmaceutical stock Archives
Cabot Undervalued Stocks Advisor Weekly Update
We have obviously lived through a very difficult period in the stock market recently, from which most of the portfolio stocks are recovering or have already recovered. Hopefully we will not see another similarly ugly stock market downturn for several years, but there no...
Read More
Cabot Undervalued Stocks Advisor Weekly Update
You may have noticed that the price of West Texas crude oil is up about 48% since it bottomed in late December.
Read More
Cabot Undervalued Stocks Advisor Weekly Update
The March flooding in Nebraska and neighboring Midwest and Great Plains states is devastating to farmers, crops and livestock. Consumers can expect prolonged food price inflation that reaches around the globe.
Read More
Cabot Undervalued Stocks Advisor Weekly Update
U.S. stocks markets are now continuing their rebound from the horrendous fourth-quarter 2018 market action. The S&P 500 and NASDAQ indexes look quite bullish, while the Dow Jones Industrial Average (DJIA) lags a bit.
Read More
Cabot Undervalued Stocks Advisor Weekly Update
I’m as “political” as they come, but I don’t make investing decisions based on politics. I make my decisions based on corporate successes (which show up via profit and revenue growth), economic facts (definitely not economic speculation) and stock market trends.
Read More
Cabot Undervalued Stocks Advisor Weekly Update
I haven’t added any new stocks for a while because we’ve already got 30 stocks in the portfolios. Our current stocks have mostly been rising: the good, the bad and the ugly. However, I always have a good list of stocks that are in...
Read More
Cabot Undervalued Stocks Advisor Weekly Update
U.S. stocks continue to defy gravity, with their audacious 2019 year-to-date gains mirroring their equally extreme fourth quarter 2018 descent.
Read More
Cabot Undervalued Stocks Advisor Weekly Update
U.S. stocks delivered great performance in January and are now taking a breather. As such, I expect the S&P 500 index to trade between 2625 and 2825 for a while. The trading range might end up being a little higher or a little but...
Read More
Cabot Undervalued Stocks Advisor Weekly Update
The stock market recovery continues in a slightly better style than I had hoped for. I had expected big upswings followed by pullbacks, which is normal for a recovery.
Read More
Cabot Undervalued Stocks Advisor Weekly Update
Crista writes about four patterns she is looking at in the market.
Read More
Cabot Undervalued Stocks Advisor Weekly Update
Crista is adding a new stock to the Growth Portfolio, it's one of the world’s largest producers of nitrogen products, serving customers on six continents.
Read More
Cabot Undervalued Stocks Advisor Weekly Update
This will be a busy week for Wall Street as analysts speak with the companies within their stock purviews and write updated research reports. I expect to relay lots of changes in consensus earnings estimates in next week’s update.
Read More
More Top Performers of 2015
Pharmas and Biotechs Dominated in 2015—Will They Do It Again in 2016?
In my January 9 Cabot Wealth Advisory, I wrote about the three top performers of 2015. Today, I take a look at the next nine top performers of 2015.
NeoPhotonics (NPTN) 3.37 to +223%...
Read More
More Top Performers of 2015
In my January 9 Cabot Wealth Advisory, I wrote about the three top performers of 2015. Today, I take a look at the next nine top performers like NeoPhotonics (NPTN), 5 Intra-Cellular Therapies (ITCI) and others.
Read More
How to Stop Being a Stock Chump
A person stops being a chump by finding a successful investing system that makes sense to them and then following it!
Read More
ArQule, Inc. (ARQL)
Today’s Daily Alert brings a new low-priced pharmaceutical stock idea from The CHEAP Investor.
“ArQule, Inc. (ARQL) engages in the research and development of cancer therapeutics directed toward molecular targets and biological processes. Its lead product candidate tivantinib (ARQ 197) is an inhibitor of c-Met...
Read More
Enter Your Log In Credentials
- Lost your password? Create New Password
- No account? Sign up